fda warning letters compounded semaglutide tirzepatide september 2025 Issues to 30 Telehealth Companies Over Misleading GLP-1 RA Marketing FDA sends warning letter after

The preparation of the compounded medicine is subject to applicable local regulations and standards

Headaches and fatigue can sometimes be linked to reduced calorie intake, dehydration, or electrolyte shifts

Glucagon-like peptide-1 (GLP-1) is an incretin secretory molecule

It might mean the dose needs increasing, or there are dietary or lifestyle factors interfering with results

Tirzepatide, the active ingredient in Mounjaro, works best when injected on a consistent weekly schedule regardless of meal timing

In rare cases, you may experience more severe side effects such as: Allergic reactions Hypoglycemia (low blood sugar) Diabetic retinopathy complications Inflammation of the pancreas (pancreatitis) Gallbladder or kidney disease Some studies have also shown that GLP-1 medications may increase your risk of developing thyroid tumors and endocrine system disorders